Biogen Tops Q2 Estimates but Slashes Full-Year EPS Outlook by ~15%, Citing Apellis Dilution and Pipeline Costs
BIIB sits 61% above its 52-week low of $124.556.
Summary
Biogen posted Q2 revenue of $2.74B and Non-GAAP EPS of $3.60, beating estimates, but cut full-year EPS guidance by ~15% to $12.00–$13.00, citing Apellis dilution and pipeline milestone charges.
Key Events · Earnings and Guidance · BIIB
-
Q2 Beat Overshadowed by Guidance Cut
While Q2 revenue of $2.74B (+3% YoY) and Non-GAAP EPS of $3.60 topped consensus, full-year 2026 Non-GAAP EPS guidance was lowered to $12.00–$13.00 from $14.25–$15.25, a ~15% reduction.
-
Growth Portfolio Surpasses Legacy MS
Driven by SPINRAZA, SKYCLARYS, and newly added SYFOVRE/EMPAVELI, Growth Portfolio revenue hit $1.06B (+24% YoY), exceeding the legacy MS portfolio for the first time.
-
Apellis Acquisition Adds Revenue, Dilution
The $5.3B Apellis acquisition closed May 14, contributing $127.8M in Q2 revenue from SYFOVRE and EMPAVELI, but is expected to dilute full-year Non-GAAP EPS by ~$0.85.
-
Pipeline Milestones Weigh on Earnings
Acquired IPR&D and milestone charges of ~$3.00 per share, including a $164M Q2 expense, drove the guidance cut; five registrational readouts are expected over the next four quarters.
Analysis · BIIB · Life Sciences
A strong second quarter saw revenue reach $2.74B and Non-GAAP EPS hit $3.60, both above consensus, fueled by 24% growth in the Growth Portfolio—which, for the first time, eclipsed the legacy MS franchise. Yet the company lowered its full-year 2026 Non-GAAP EPS guidance to $12.00–$13.00, down from $14.25–$15.25, pointing to roughly $3.00 in acquired IPR&D and milestone charges plus about $0.85 in dilution from the Apellis acquisition. The guidance reduction overshadows the beat and signals that integration costs and pipeline investment will weigh on near-term earnings, even as the Apellis deal brings high-growth assets like SYFOVRE and EMPAVELI. With five registrational readouts slated for the next four quarters, the catalyst path is rich, but the lowered profit outlook raises questions about the pace of return on heavy R&D spending.
At the time of this filing, BIIB was trading at $201.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.4B. The 52-week trading range was $124.56 to $219.72. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.